Regulatory News:
Skanska (STO:SKAB) has been chosen as construction manager for expansion of a pharmaceutical facility in New Jersey. The contract amount totals USD 60.5 M, or approximately SEK 410 M, which will be included in order bookings for the fourth quarter. The customer is one of Skanska's repeat customers within the pharmaceutical industry.
The project involves construction of a three-story, approximately 9.300-square-meter building and renovation of an existing 11,600-square-meter building. Among other objectives, the project will improve and expand the company's supply operations and logistics management.
This is the fifth project that Skanska is performing at the facility since 2005. Previous projects include office and laboratory renovations, a new parking deck, cafeteria and fitness center as well as a new clinical manufacturing structure.
Skanska USA Building is a leading U.S. provider of construction, general contracting, design and design-build services. The company also provides pharmaceutical validation services to clients. Customers represent a broad spectrum of American industries, including the pharmaceutical, healthcare, educational, electronics, infrastructure, sports and entertainment industries. The company is based in Parsippany, New Jersey and has approximately 3,900 employees. Revenues totaled approximately SEK 30 billion in 2006.
In addition to a number of biotechnology facilities throughout the U.S. and Puerto Rico, Skanska USA Building is currently constructing the New Meadowlands Stadium and managing an extensive renovation of UN Headquarters in New York City.
This and previous releases can also be found at www.skanska.com
Skanska AB may be required to disclose the information provided herein pursuant to the Securities Markets Act.
Skanska is one of the world's leading construction groups with expertise in construction, development of commercial and residential projects and public-private partnerships. The Group currently has 56,000 employees in selected home markets in Europe, in the US and Latin America. Headquartered in Stockholm, Sweden and listed on the Stockholm Stock Exchange, Skanska's sales in 2006 totaled SEK 126 billion.
This information was brought to you by Cision http://newsroom.cision.com
Skanska (STO:SKAB) has been chosen as construction manager for expansion of a pharmaceutical facility in New Jersey. The contract amount totals USD 60.5 M, or approximately SEK 410 M, which will be included in order bookings for the fourth quarter. The customer is one of Skanska's repeat customers within the pharmaceutical industry.
The project involves construction of a three-story, approximately 9.300-square-meter building and renovation of an existing 11,600-square-meter building. Among other objectives, the project will improve and expand the company's supply operations and logistics management.
This is the fifth project that Skanska is performing at the facility since 2005. Previous projects include office and laboratory renovations, a new parking deck, cafeteria and fitness center as well as a new clinical manufacturing structure.
Skanska USA Building is a leading U.S. provider of construction, general contracting, design and design-build services. The company also provides pharmaceutical validation services to clients. Customers represent a broad spectrum of American industries, including the pharmaceutical, healthcare, educational, electronics, infrastructure, sports and entertainment industries. The company is based in Parsippany, New Jersey and has approximately 3,900 employees. Revenues totaled approximately SEK 30 billion in 2006.
In addition to a number of biotechnology facilities throughout the U.S. and Puerto Rico, Skanska USA Building is currently constructing the New Meadowlands Stadium and managing an extensive renovation of UN Headquarters in New York City.
This and previous releases can also be found at www.skanska.com
Skanska AB may be required to disclose the information provided herein pursuant to the Securities Markets Act.
Skanska is one of the world's leading construction groups with expertise in construction, development of commercial and residential projects and public-private partnerships. The Group currently has 56,000 employees in selected home markets in Europe, in the US and Latin America. Headquartered in Stockholm, Sweden and listed on the Stockholm Stock Exchange, Skanska's sales in 2006 totaled SEK 126 billion.
This information was brought to you by Cision http://newsroom.cision.com
© 2007 Business Wire
